Shots:

• The CHMP has adopted the positive opinion recommending the approval of Theramex’s  Livogiva (biosimilar- teriparatide) intended for the treatment of osteoporosis and will be available as a solution for injection (20 micrograms/80 microliters)
• The CHMP has also recommend marketing authorization to EuroGenerics’ Qutavina (biosimilar- teriparatide) to treat osteoporosis- also available as a solution for injection (20 micrograms/80 microliters)
• Both Livogiva and Qutavina are the biosimilar referencing Lilly’s Forsteo (teriparatide) which has received authorization in EU in 2003

Theramex- EuroGenerics to read full press release/ article | Ref: EMA | Image: Theramex & EuroGenerics